Pre-Eclampsia Clinical Trial
— PRENBOfficial title:
Short Term Neurobehavioural Outcomes in Late Preterm Neonates Born to Pre Eclamptic Mothers : a Prospective Observational Study
Verified date | March 2017 |
Source | Lady Hardinge Medical College |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Hypertensive disorders are the most common medical complications in pregnancy and major
causes of maternal, fetal, and neonatal morbidity and mortality. Fifty percent of
hypertensive disorders of pregnancy are defined as pre eclampsia, the most important
manifestation of the disease.
Preeclampsia is also a significant risk factor in the development of IUGR and represents the
most common cause of IUGR in the nonanomalous infant. The incidence of thrombocytopenia,
neutropenia and Bronchopulmonary dysplasia is also increased in neonates with preeclampsia.
The neurodevelopmental outcomes infants exposed to preeclampsia are highly variable. The
study by Gray et al showed that preeclampsia is associated with a decreased risk of cerebral
palsy. They also found a protective effect of maternal preeclampsia on cerebral palsy
regardless of exposure to magnesium sulfate. However, contrary to this, study conducted by
Shao-Wen Cheng et al has showed that infants born to pre-eclamptic mothers had lower MDI
scores at 24 months of age (P= 0.04) as compared to infants without maternal pre-eclampsia.
The study by Szymonowicz et al showed that neonates born to pre-eclamptic mothers had a
significantly lower mean mental developmental index, and significantly more of these
children had one or more impairments compared with the control group at 2 years of age. The
neurodevelopmental outcomes in neonates born to preeclamptic mothers therefore remain
inconclusive. Recently the role of neurobehaviour being evaluated early at 37-40 weeks of
CGA is being predicted as an useful adjunct to the 12-18 month full neurodevelopmental
assessment. This assumes significance in the context of initiation of early stimulation and
objectivised individual developmental rehabilitation regimens for these infants.
Status | Completed |
Enrollment | 60 |
Est. completion date | October 2015 |
Est. primary completion date | October 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 34 Weeks to 37 Weeks |
Eligibility |
INCLUSION CRITERIA - Late preterm infants - Pre eclampsia in mothers - Parental Consent EXCLUSION CRITERIA - Major congenital malformation - Eclampsia ( seizures in mother) - Mothers on antipsychotic drugs - Clinical Chorioamnionitis ( fever > 100.4ยบ F, uterine fundal tenderness, maternal tachycardia (>100/min), fetal tachycardia (>160/min) and purulent or foul amniotic fluid ) - Birth Asphyxia (Apgar score of less than 7 at 1 minute of age) - Multiple gestation. |
Country | Name | City | State |
---|---|---|---|
India | Lady Hardinge Medical College,New Delhi | Delhi |
Lead Sponsor | Collaborator |
---|---|
Lady Hardinge Medical College |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Neurobehavioral score by NAPI at 40 weeks of corrected gestation for MDV(Motor development- vigor) and AO(Alertness-orientation) | Neurobehavioral score by NAPI at 40 weeks of corrected gestation for MDV(Motor development- vigor) and AO(Alertness-orientation) | 22 MONTHS | |
Secondary | Incidence of small for gestational age babies. | Incidence of small for gestational age babies. | 22 MONTHS | |
Secondary | Need for NICU admission | Need for NICU admission | 22 MONTHS |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03299777 -
Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan
|
N/A | |
Completed |
NCT03650790 -
C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies
|
N/A | |
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Not yet recruiting |
NCT03302260 -
Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial
|
N/A | |
Completed |
NCT02911701 -
Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
|
Phase 4 | |
Completed |
NCT01911494 -
Community Level Interventions for Pre-eclampsia
|
N/A | |
Terminated |
NCT02025426 -
Phenylephrine Versus Ephedrine in Pre-eclampsia
|
Phase 4 | |
Completed |
NCT01352234 -
Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
|
Phase 4 | |
Active, not recruiting |
NCT02031393 -
Establishing First Trimester Markers for the Identification of High Risk Twin
|
N/A | |
Terminated |
NCT00141310 -
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
|
Phase 2 | |
Completed |
NCT00157521 -
L-Arginine in Pre-Eclampsia
|
Phase 3 | |
Completed |
NCT04795154 -
Prenatal Yoga as Complementary Therapy of Preeclampsia
|
N/A | |
Completed |
NCT00004399 -
Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia
|
N/A | |
Completed |
NCT00005207 -
Renin and Prorenin in Pregnancy
|
N/A | |
Recruiting |
NCT04551807 -
Natural Versus Programmed Frozen Embryo Transfer (NatPro)
|
Phase 3 | |
Terminated |
NCT04092829 -
Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer
|
N/A | |
Recruiting |
NCT06067906 -
Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients
|
N/A | |
Recruiting |
NCT06317467 -
Role of Anti-C1q Autoantibodies in Pregnancy
|
||
Completed |
NCT02218931 -
ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes
|
N/A | |
Active, not recruiting |
NCT04484766 -
Preeclampsia Associated Vascular Aging
|